Cleveland Clinic's 2020 Management of Checkpoint Inhibitor-Related Toxicity
Adverse Events - Immunobiology of CPIs and Autoimmunity: PD-1 Pathway and Activity Is Similar to That Displayed by Cancer Patients on Anti-PD-1 Therapy
Comments 0
Login to view comments.
Click here to Login